<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352090</url>
  </required_header>
  <id_info>
    <org_study_id>SYLVI030785</org_study_id>
    <nct_id>NCT02352090</nct_id>
  </id_info>
  <brief_title>Synthetic vs Natural Estrogen in Combined Oral Contraception</brief_title>
  <acronym>SYLVI</acronym>
  <official_title>Synthetic vs Natural Estrogen in Combined Oral Contraception- Effect on Insulin Sensitivity, Coagulation, Inflammation and Endometrium - a Comparison With a Progestin-only Preparation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to compare the metabolic effects of natural estradiol and
      synthetic ethinylestradiol used in combined oral contraception in healthy women. A
      progestin-only preparation will be used in comparison. The main goal is to study the effects
      on glucose metabolism, coagulation and a markers of chronic inflammation (such as hs-CRP).
      Our hypothesis is that the natural estradiol preparation will influence blood glucose levels,
      markers of coagulation and chronic inflammation less than the ethinylestradiol preparation.
      The progestin-only preparation will not effect these parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in plasma glucose concentrations during 'Two hour Oral glucose tolerance test' at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Plasma glucose concentrations during 'two hour oral glucose tolerance test' (2hOGGT) conducted at baseline and at 9 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Glycosylated Hemoglobin</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Glycosylated hemoglobin (HbA1c%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in serum insulin at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change in serum insulin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in marker of chronic inflammation at 5 weeks</measure>
    <time_frame>baseline and 5 weeks</time_frame>
    <description>Plasma concentrations of acute phase protein 'C reactive protein' (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in marker of chronic inflammation at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Plasma concentrations of acute phase protein 'C reactive protein' (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mononuclear cell inflammatory response at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Mononuclear cell Interleukin 6 secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mononuclear cell inflammatory response at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Mononuclear cell Nuclear factor kappa-light-chain-enhancer of activated B cells -activation (NFkB-activation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total plasma cholesterol at 5 weeks</measure>
    <time_frame>baseline and 5 weeks</time_frame>
    <description>Plasma concentrations of cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total plasma cholesterol at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Plasma concentrations of total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma Low-Density Lipoprotein (LDL) at 5 weeks</measure>
    <time_frame>baseline and 5 weeks</time_frame>
    <description>Plasma concentration of Low-Density Lipoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma Low-Density Lipoprotein (LDL) at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Plasma concentration of Low-Density Lipoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma High-Density Lipoprotein (HDL) at 5 weeks</measure>
    <time_frame>baseline and 5 weeks</time_frame>
    <description>Plasma concentration of High-Density Lipoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma High-Density Lipoprotein (HDL) at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Plasma concentration of High-Density Lipoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma triglyceride concentrations at 5 weeks</measure>
    <time_frame>baseline and 5 weeks</time_frame>
    <description>Plasma concentration triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma triglyceride concentrations at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Plasma concentration triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Prothrombin fragment I and II at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Prothrombin fragment I and II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum D-dimer concentrations at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Activated Protein C resistance at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Activated protein C resistance</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Endometrial proliferation at 9 weeks</measure>
    <time_frame>9 weeks</time_frame>
    <description>Endometrial biopsy with immunohistological evaluation of markers of proliferation</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Anti Mullerian Hormone concentrations at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Change in Serum concentrations of anti-mullerian hormone reflecting ovarian reserve</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days with vaginal bleeding</measure>
    <time_frame>9 weeks</time_frame>
    <description>Self-reported days of bleeding in bleeding diary.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patterns of vaginal bleeding</measure>
    <time_frame>9 weeks</time_frame>
    <description>Self- reported clusters of bleeding days in bleeding diary.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Quality of Life scores at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Quality of life questionnaire (EQ-5D questionnaire)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Anxiety scores at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>State-Trait Anxiety Inventory (STAI) questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in sexuality scores at 9 weeks</measure>
    <time_frame>baseline and 9 weeks</time_frame>
    <description>Mccoy female sexuality questionnaire (MFSQ) questionnaire</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Synthetic estrogen + progestin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ethinyl estradiol / dienogest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natural estrogen + progestin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estradiol valerate / dienogest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progestin-Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dienogest</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinyl estradiol / dienogest</intervention_name>
    <description>One tablet orally for 9 weeks, continuous use</description>
    <arm_group_label>Synthetic estrogen + progestin</arm_group_label>
    <other_name>Valette, ATC code G03AA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol valerate / dienogest</intervention_name>
    <description>One tablet orally for 9 weeks, continuous use</description>
    <arm_group_label>Natural estrogen + progestin</arm_group_label>
    <other_name>Qlaira, ATC code G03AB08</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest</intervention_name>
    <description>One tablet orally for 9 weeks, continuous use</description>
    <arm_group_label>Progestin-Only</arm_group_label>
    <other_name>Visanne, ATC code G03D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 19-24.9, regular menstrual cycles (21-35 days), a minimum of 2 months without any
             hormonal contraceptives, no contraindications for use of hormonal contraception

        Exclusion Criteria:

          -  Polycystic ovaries, hypertension, smoking, alcohol abuse, pregnancy, lactation,
             abnormal result in pre-screening 2h oral glucose tolerance test, regular medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oskari Heikinheimo, Prof., PhD., MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital, Department of Gynecology and Obstetrics. Helsinki Univeristy, Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juha Tapanainen, Prof., PhD, MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital, Department of Gynecology and Obstetrics. Helsinki Univeristy, Medical Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terhi Piltonen, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital, Department of Gynecology and Obstetrics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annina Haverinen, MD, PhD student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Department of Gynecology and Obstetrics. Helsinki University, Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Kätilöopisto Maternity Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital, Department of Gynecology and Obstetrics</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Annina Haverinen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Contraception, oral</keyword>
  <keyword>Ethinyl Estradiol</keyword>
  <keyword>Estradiol Valerate</keyword>
  <keyword>Dienogest</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Chronic inflammation</keyword>
  <keyword>Coagulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Nandrolone</mesh_term>
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

